The Phase 3 NIAGARA trial, presented at ASCO GU 2025, provides compelling evidence supporting perioperative durvalumab (D) plus neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC). The study highlights significant survival benefits, reinforcing the role of immunotherapy in the perioperative setting.
Key Findings:
33% reduction in the risk of metastases or death
31% lower risk of bladder cancer mortality
Higher pathologic complete response (pCR) rate with durvalumab + NAC (37% vs 28% compared to NAC alone) Improved event-free survival (EFS) and overall survival (OS) in both pCR and non-pCR groups
A manageable safety profile, with low-grade immune-related adverse events
These results, unveiled at ASCO GU 2025, reinforce durvalumab as a potential new perioperative standard of care for MIBC. The exploratory analysis further highlights the prognostic value of pathologic complete response (pCR), underscoring its impact on long-term survival outcomes.
A special acknowledgment to the dedicated research team behind this work, whose contributions continue to shape the future of bladder cancer treatment.
Read more: https://lnkd.in/ePK693Xa
